Search Videos and More
A Surgical Milestone: Miami Cancer Institute First in Southeast Region to Complete Uterine Transposition on Cancer Patient
Miami Cancer Institute, part of Baptist Health South Florida, is the first cancer center to conduct a successful uterine transposition surgery on a cancer patient in the Southeast region.New Drug Extends Survival for Late-Stage Prostate Cancer Patients
Baptist Health Miami Cancer Institute is among the first cancer centers in the region to offer an innovative radiopharmaceutical therapy that can extend survival and increase quality of life for patients with stage 4 metastatic prostate cancer, according to radiation oncologist Adeel Kaiser, M.D.Gallbladder Cancer: Progress and Hope for Future Breakthroughs
For Gallbladder Cancer Awareness Month, Horacio J. Asbun, MD, and Domenech Asbun, MD, shared their thoughts and strategies for treating patients with this disease from the surgical and clinical sides.Study: Ablative Stereotactic Magnetic Resonance-Guided Adaptive Radiation Therapy May Improve Overall Survival in Patients with Pancreatic Cancer
A study co-led by researchers at Miami Cancer Institute, part of Baptist Health South Florida, found that ablative stereotactic magnetic resonance (MR)-guided adaptive radiation therapy may improve local control (LC) and overall survival (OS) in patients with borderline resectable (BRPC) and locally advanced pancreas cancer (LAPC).When Your Patient Needs an Oral Medicine Evaluation
Whether your patient is being treated for cancer, has an autoimmune disease or an inflammatory condition that is causing an oral problem apart from the teeth and gums, they may benefit from an evaluation and treatment by an oral medicine specialist.Miami Cancer Institute Leads First-in-World Brain Metastasis Trial
Baptist Health Miami Cancer Institute is leading a groundbreaking clinical trial that is studying the use of a new medication combined with stereotactic radiosurgery to combat metastatic brain cancer.Miami Cancer Institute Publication Analyzes Role of Tissue-Agnostic Therapies for the Treatment of Primary Brain Tumors
Researchers from Miami Cancer Institute, part of Baptist Health South Florida, recently published a study in Trends in Cancer that analyzes the use of tissue-agnostic therapeutics in patients with primary brain tumors (PBTs). The publication describes the current and potential impact of tissue-agnostic therapies on the management of PBTs. As part of the publication, the researchers discuss data from clinical trials of tissue-agnostic targets for PBTs in the context of challenges in managing these tumors. They also describe additional tissue-agnostic targets that hold promise for benefiting patients with PBTs.Miami Cancer Institute Precision Oncology Symposium, Second Annual
Live Symposium Friday-Saturday, April 19-20, 2024 The Ritz-Carlton, Coconut Grove, Miami, FloridaAdvanced Prostate Cancer: Genetic Testing an Invaluable Tool
A study led by Baptist Health Miami Cancer Institute shows that patients with TP53, RB1 and PTEN mutated prostate cancer have a lower overall survival rate than patients who are biomarker negative. The results emphasize the importance of genetic testing for all advanced cancer patients, the researchers say.Baptist Health Miami Cancer Institute First in U.S. to Offer New Robotic Technology for Liver Cancer
In May of 2023, Govindarajan Narayanan, M.D., became the first physician to use the Epione robot in the U.S., performing an image-guided microwave ablation on a patient with a liver tumor.Miami Cancer Institute to Host Fifth Global Summit on Immunotherapies for Hematologic Malignancies
Miami Cancer Institute, part of Baptist Health South Florida, announced it will host the Fifth Annual Global Summit on Immunotherapies for Hematologic Malignancies, to be held March 8-9, 2024, at the JW Marriott Hotel in Brickell, Miami, Fla.Miami Cancer Institute Achieves AAHRPP Accreditation
The Association for Accreditation of Human Research Protection Programs has recognized Miami Cancer Institute for promoting ethically sound and safe human subject research practices.